Cubriva 75mg Tablet

Cubriva 75mg Tablet contains the active ingredient Brivaracetam, which belongs to the class of antiepileptic drugs. It is prescribed for the treatment of epilepsy, specifically as adjunctive therapy for partial-onset seizures in adults and children aged four years and older. Brivaracetam works by modulating synaptic vesicle protein 2A (SV2A), which is involved in the regulation of neurotransmitter release, thereby reducing the occurrence of seizures.

Uses:

Cubriva 75mg Tablet is used as adjunctive therapy for the management of partial-onset seizures in patients with epilepsy. It is typically prescribed in combination with other antiepileptic medications to improve seizure control. Brivaracetam helps to reduce the frequency and severity of seizures, allowing patients to better manage their condition and improve their quality of life.

Dosage:

The dosage of Cubriva 75mg Tablet is determined by the healthcare provider based on factors such as the patient’s age, weight, renal function, and response to treatment. It is usually taken orally twice daily, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed. Patients should follow the prescribed dosage and administration instructions carefully.

Side Effects:

Common side effects associated with Cubriva 75mg Tablet may include dizziness, drowsiness, fatigue, headache, nausea, vomiting, and irritability. These side effects are usually mild and transient. In some cases, more serious side effects such as behavioral changes, mood swings, or allergic reactions may occur. Patients should report any adverse reactions to their healthcare provider promptly.

Precautions:

Before using Cubriva 75mg Tablet, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. This medication may interact with other drugs, so it’s essential to review the patient’s medication regimen to avoid potential interactions. Patients with a history of psychiatric disorders should use Cubriva with caution.

When Not to Use:

Cubriva 75mg Tablet is contraindicated in patients with a known hypersensitivity to Brivaracetam or any other components of the medication. It should not be used as monotherapy for epilepsy or as the initial treatment for seizures. Patients with a history of significant psychiatric disorders or suicidal ideation should also avoid this medication.